Mode
Text Size
Log in / Sign up

Ofloxacin shows superior relative efficacy for pain control after photorefractive keratectomyTopical and systemic drugs help manage pain after eye surgery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider Ofloxacin for superior relative efficacy in post-PRK pain control and Diclofenac for a favorable safety profile.

This systematic review and network meta-analysis evaluated various topical and systemic pharmacological agents for pain management in patients undergoing photorefractive keratectomy (PRK). The analysis included 2,797 patients to rank interventions based on SUCRA values.

Key findings indicate that Ofloxacin (SUCRA = 0.84) and Proparacaine (0.76) were the top-ranked topical agents for analgesia. Among systemic options, Codeine combined with Acetaminophen (0.71) ranked highest. However, the authors note that effect sizes for most interventions relative to placebo spanned the line of no effect.

Regarding safety, Diclofenac (SUCRA = 0.81), Ketorolac (0.70), and Nepafenac (0.53) demonstrated optimal profiles, with Diclofenac specifically noted for the most favorable safety profile. The study notes that safety conclusions are limited because only seven studies reported highly heterogeneous adverse event data.

Clinical application is tempered by the fact that cross-route comparisons are susceptible to transitivity violations. While Ofloxacin shows superior relative efficacy for pain control, the evidence for specific superiority over placebo is not clearly defined due to overlapping confidence intervals.

How this fits prior evidence

This finding addresses a gap in managing post-operative pain following photorefractive keratectomy (PRK). While previous coverage has evaluated pharmacological interventions for hand-foot syndrome using topical diclofenac or celecoxib, this study specifically focuses on the immediate postoperative analgesic efficacy of agents like Ofloxacin and systemic combinations like Codeine with Acetaminophen.

Managing pain after a photorefractive keratectomy (PRK) is vital for patient comfort. A large review of 2,797 patients looked at different ways to handle this discomfort, comparing both topical treatments applied directly and systemic medications taken by the body.

For local relief, Ofloxacin and Proparacaine ranked as the top-performing topical agents. When looking at systemic options, a combination of Codeine and Acetaminophen ranked highest for pain control. While these rankings show which drugs are most effective relative to others, many of the results were close enough to placebo that some differences were not clearly defined.

Safety is also a major factor in choosing the right treatment. Diclofenac was found to have the most favorable safety profile among the options tested. However, it is important to note that these safety conclusions are based on only seven studies with varied data. Because of this limited amount of reporting, doctors should weigh these findings carefully when creating a plan for patients.

What this means for you:
Ofloxacin ranks highest for topical pain relief, while Diclofenac shows the best safety profile after eye surgery.

Common questions

Which topical medication is best for pain after surgery?

Ofloxacin and Proparacaine were the top-ranked topical agents for pain control. Ofloxacin specifically showed superior relative efficacy for managing pain compared to other options in the study.

What systemic medications help with post-surgery pain?

Among systemic options, the combination of Codeine and Acetaminophen ranked highest for pain management. These results are based on a review of 2,797 patients.

Which medication is safest for patients to use?

Diclofenac offered the most favorable safety profile among the drugs tested. However, because only seven studies reported adverse event data, these specific safety conclusions are limited.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
ObjectiveTo systematically evaluate the comparative efficacy and safety of common pharmacological strategies for managing post-photorefractive keratectomy (PRK) eye pain through a network meta-analysis, providing evidence-based guidance for clinical medication.MethodsRandomized controlled trials (RCTs) were systematically retrieved from Cochrane Library, Web of Science, PubMed, and EMbase (from inception to November 15, 2025). Using R Studio, we conducted a network meta-analysis to assess differences in Visual Analogue Scale (VAS) scores and adverse events across pharmacological interventions. SUCRA (Surface Under the Cumulative Ranking) values were calculated to determine the relative ranking of interventions, while accounting for heterogeneities in administration timing and dosage.ResultsA total of 28 studies were included, involving 2,797 patients. In route-stratified analyses, Ofloxacin (SUCRA = 0.84) and Proparacaine (0.76) were the top-ranked topical agents for analgesia, while Codeine combined with Acetaminophen (0.71) ranked highest among systemic agents. The exploratory combined network yielded identical top-three rankings, though these cross-route comparisons are susceptible to transitivity violations. Notably, effect sizes for most interventions relative to placebo spanned the line of no effect. Regarding safety, Diclofenac (SUCRA = 0.81), Ketorolac (0.70), and Nepafenac (0.53) demonstrated the optimal profiles. The highest numbers of adverse events occurred with Pregabalin (39 cases), Fentanyl (20 cases), and Codeine combined with Acetaminophen (13 cases); however, safety conclusions remain limited as only seven studies reported highly heterogeneous adverse event data.ConclusionOfloxacin demonstrates superior relative efficacy for pain control following PRK, while Diclofenac offers the most favorable safety profile. Clinicians should synthesize these comparative findings with individual patient profiles to optimize drug selection, ensuring a balanced approach between effective pain relief and minimized adverse risks.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251238092, CRD420251238092.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.